AI Transforming Drug Discovery: Next Biotech Boom Ahead
Artificial intelligence is turbocharging drug discovery, cutting years from development timelines and sparking a surg...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
134 articles
Wall Street Expects This Growth Stock to Double Soon
A biotech growth stock has surged 70% this year as it heads into pivotal phase 3 data and regulatory steps. Here’s wh...
Should Moderna Before Aug.: A Clear Investor Guide for 2026
As Aug. 5 looms, investors debate whether Moderna belongs in a refreshed portfolio. This guide breaks down the cataly...
Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
A Blood Test That Screens 50+ Cancers Moves Closer
A breakthrough blood test that screens for 50+ cancers is edging toward real-world use. This article breaks down what...
Moderna Some Approvals Ahead: Is the Stock a Buy?
Moderna’s growth story now centers on a broader mRNA pipeline and FDA decisions. This guide breaks down the upcoming ...
Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Parabilis Soared Biggest Biotech: Is It Too Late to Buy?
A record biotech IPO backdrop has investors buzzing about Parabilis Medicines. This guide breaks down what the surge ...
Is Viking Therapeutics Stock Going to $100? Key Signals
Viking Therapeutics sits at the intersection of biotech risk and big growth potential. This article breaks down what ...
Lilly Novo Nordisk Battle Intensifies as Obesity Drugs Surge
Eli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
Prediction: Pfizer Stock Could Double If Pipeline Delivers
Pfizer stock is navigating a pivot from COVID-era revenues to a broader drug portfolio. Analysts weigh the odds of a ...
Zealand Pharma Loses Fifth of Value After Trial Dropouts
Danish biotech Zealand Pharma saw its stock slide after disclosing a 20% dropout rate in its weight-loss drug trial d...